Schott AG – A global leader in specialty glass and glass-ceramics manufacturing

Repeat investments underscore Schott’s commitment to pharmaceutical business in India

0
301
SCHOTT Glass India manufacturing plant at Jambusar, India

Schott is a leading international technology group in the areas of specialty glass and glass-ceramics. Founded in 1884, the company has more than 130 years of expertise in development, materials, and technology, and offers a broad portfolio of high-quality products and intelligent solutions. Mainz, Germany headquartered Schott is solely owned by the Carl Zeiss Foundation one of the oldest private and largest science-promoting foundations in Germany.

Since 1998, Schott has played a key role in the development of India’s pharmaceutical industry by manufacturing high-quality pharmaceutical tubing products in Jambusar. The company offers a broad product portfolio, including ampoules, cartridges, vials, and syringes made of glass and COC polymer. Its state-of-the-art manufacturing plants and products comply with the international quality standards for pharmaceutical needs. The company offers a complete portfolio of high-quality Type I (FIOLAX and BORO-8330) and Type III (ILLAX and AR-GLAS) glass tubing with a dedicated specification for each application (syringes, cartridges, vials, and ampoules).

USP of Schott products

We met with Patrick Markschlaeger, executive vice president – Tubing of Schott AG, at CPhI P-Mech Greater Noida, where he gave us an insight into the company’s working module. “Schott has been developing and manufacturing a comprehensive selection of special glasses for pharmaceutical packaging, such as glass for syringes, vials, ampoules, and cartridges. The high-quality FIOLAX has been the epitome of the highest quality, premium glass since 1911. Schott uses the new era of quality processing perfeXion, which offers a transition from statistical quality control to 100% inspection of each FIOLAX tube. A broad range of container geometries, quality levels and controlled surface chemistry across locations enables Schott to tailor the primary packaging solution to customers’ specific needs. Schott’s global footprint and uniform global standards for high-quality products are also one of the biggest USPs of the company,” he said.

Patrick Markschlaeger, executive vice president – Tubing of Schott AG

Demand is higher than supply

Speaking about the Indian pharmaceutical glass application market and Schott’s contribution to it, he said, “The current situation is very dynamic, where demand is much higher than supply, and Schott feels this will continue to be the same for at least a couple of years. As the export of Indian pharmaceutical products increases, the demand for the best quality products like Schott will increase. With the same understanding, Schott has already invested a substantial amount in the expansion of its existing plant to double its current capacity.”

Schott invests in fulfilling local demands

Talking about the company’s upcoming plans and ventures, Markschlaeger said, “Concerning India, success is vital to Schott’s growth in the world market. Its domestic market represents one of the most attractive growth opportunities, and it is an excellent export hub for regional demands. The Indian pharmaceutical market is continuously growing, and Schott wants to be part of this growth; therefore, we are investing to increase capacity to fulfill local demand.”

One of the highest growing divisions for Schott Group in India is its tubing division, which completed 20 years of India operations last year. Schott intends to continue its course of sustainable, profitable growth in the current fiscal year. In 2019, the company inaugurated its new glass tank plant in Jambusar, Gujarat, which was set up with an investment of EUR 21 million (approximately Rs 165 crore). Schott also eyes rapid growth prospects for high-quality glass material driven by the pharma industry. Moreover, the company has lined up additional investments of EUR 26 million (approximately Rs 200 crore) for yet another tank plant this year, which will double its total capacity by 2020.

The new production plant, with a combined investment of EUR 47 million (approximately Rs 370 crore), will double the capacity of Schott Glass India’s manufacturing unit. In addition, it will allow the group to produce its highly specialized FIOLAX tubing material for both domestic and export demands. Schott began the construction of its first new facility last year on the occasion of completing two decades of operations in India.

Schott is growing

Speaking about the growth of the company, Markschlaeger said, “Globally, Schott has achieved solid growth over the last many years. In the fiscal year 2017-2018, Schott has achieved currency-adjusted sales of 6.3%. We have also achieved a record annual profit of EUR 208 million (approximately Rs 1687 crore). In India, Schott saw sales of approximately Rs 341 crore – an increase of 32.6%, which converted into 26.2% after currency effects. Key growth driver segments for India were Schott’s tubing, pharma-packaging and flat glass for cooking.”

Regulatory compliances

Schott actively takes part in forming the regulatory landscape of the packaging industry and therefore is always aware of upcoming changes. “Schott is, in fact, among the benefactors of the efforts made by the Government of India in creating an environment conducive for international businesses to invest and set up manufacturing facilities. We plan to continue investing in India as a part of Make in India, as we believe there is great potential in the Indian companies becoming the hub for offering pharmaceutical equipment for global pharmaceutical supply chains as well,” explained Markschlaeger.

Schott committed to expanding local footprint

Schott’s investment in India underscores its commitment to the pharmaceutical business and shows how important this business is to the Schott Group. The company believes that the main objective behind these investments is to improve its ability to supply high-quality products to the local Indian pharma companies. Its latest investment in India is part of the company’s comprehensive growth program specifically for the pharma emerging markets.

“As a company, it is our vision to play an essential part of everyone’s life. One of our business goals is to expand our activities in Asia further and to establish ourselves in our core markets with partners or with ‘greenfield investments’. We want to position Schott as a ‘global’ company, a global corporation with a strong local structure. It is Schott’s vision to serve the trends in Asia both with existing products, which may be adapted to local needs and with new product developments. India is one of our fastest-growing markets, and we see strong opportunities here,” he concluded.

As you join us today from India and elsewhere, we have a favour to ask. Through these times of ambiguity and challenge, the packaging industry in India and in most parts of the world has been fortunate. We are now read in more than 90 countries as our coverage widens and increases in impact. Our traffic as per analytics more than doubled in 2020 and many readers chose to support us financially even when advertising fell to pieces.

As we come out of the pandemic in the next few months, we hope to again expand our geography and evolve our high-impact reporting and authoritative and technical information, with some of the best correspondents in the industry. If there were ever a time to support us, it is now. You can power Packaging South Asia’s balanced industry journalism and help to sustain us by subscribing.

Subscribe Now

LEAVE A REPLY

Please enter your comment!
Please enter your name here